Literature DB >> 9139377

A field study on Nakayama and Beijing strains of Japanese encephalitis vaccines.

S Nimmannitya1, S Hutamai, S Kalayanarooj, S Rojanasuphot.   

Abstract

A field study to compare the immune response of children aged 1-6 years to Nakayama and Beijing strains JE vaccines was carried out in Mae Hong Son Province, northwest Thailand, where there was low incidence of JEV infection. The first and second dose of each vaccine was given 1-2 weeks apart and the third dose was 1 year after the second dose. Seroconversion rate was similarly high, about 94% in both groups of vaccinees. At 6 and 12 months after 2 doses of vaccines, the seroconversion rates dropped in both groups of vaccinees, so there were 10-20% of children (50-65% if cross protection was considered) susceptible to JEV infections during this period. After the third dose of vaccine, the seroconversion rate rose to 100% in both groups. The GMT in Bejing strain vaccinees were slightly higher than Nakayama strain JE vaccines. To reduce the number of susceptible children during 6-12 months after the second dose and for longer protection, the primary JE immunization should be 3 doses and the timing for the third dose should be at 6 months after the second dose. Either Nakayama or Beijing strain vaccine could be used in Thailand.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9139377

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  7 in total

1.  Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.

Authors:  Peter E Nasveld; Joanne Marjason; Sonya Bennett; John Aaskov; Suzanne Elliott; Karen McCarthy; Niranjan Kanesa-Thasan; Emmanuel Feroldi; Mark Reid
Journal:  Hum Vaccin       Date:  2010-11-01

Review 2.  Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease.

Authors:  Nagendra R Hegde; Milind M Gore
Journal:  Hum Vaccin Immunother       Date:  2017-02-22       Impact factor: 3.452

3.  Preexisting Japanese encephalitis virus neutralizing antibodies and increased symptomatic dengue illness in a school-based cohort in Thailand.

Authors:  Kathryn B Anderson; Robert V Gibbons; Stephen J Thomas; Alan L Rothman; Ananda Nisalak; Ruth L Berkelman; Daniel H Libraty; Timothy P Endy
Journal:  PLoS Negl Trop Dis       Date:  2011-10-04

4.  Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, double-blinded, randomized trial.

Authors:  Ki Wook Yun; Hoan Jong Lee; Jin Han Kang; Byung Wook Eun; Yae-Jean Kim; Kyung-Hyo Kim; Nam Hee Kim; Young Jin Hong; Dong Ho Kim; Hwang Min Kim; Sung-Ho Cha
Journal:  BMC Infect Dis       Date:  2015-01-08       Impact factor: 3.090

5.  Safety of Japanese encephalitis vaccines.

Authors:  Ya-Li Hu; Ping-Ing Lee
Journal:  Hum Vaccin Immunother       Date:  2021-10-06       Impact factor: 3.452

6.  Formalin Inactivation of Japanese Encephalitis Virus Vaccine Alters the Antigenicity and Immunogenicity of a Neutralization Epitope in Envelope Protein Domain III.

Authors:  Yi-Chin Fan; Hsien-Chung Chiu; Li-Kuang Chen; Gwong-Jen J Chang; Shyan-Song Chiou
Journal:  PLoS Negl Trop Dis       Date:  2015-10-23

Review 7.  Japanese encephalitis: the virus and vaccines.

Authors:  Sang-Im Yun; Young-Min Lee
Journal:  Hum Vaccin Immunother       Date:  2013-10-25       Impact factor: 3.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.